RESEARCH ATLASRESEARCH > HYPE
PUBLIC RESEARCH EDITION
Senescence / longevity

FOXO4-DRI

FOXO4–p53 interaction / senescent-cell apoptosis · Peptide
Also known as foxo4-dri Foxo4 Dri

Evidence at a glance

Each record keeps its own evidence class. Counts are records in this public edition, not a quality score.

Evidence gap: Route-specific human PK and absolute bioavailability are not established in the imported material.

Open in the interactive library →Compare with other compounds →

Records (1)

P

Preclinical

Preclinical

Preclinical senolytic concept

Designed to disrupt FOXO4–p53 interaction in senescent cells.

Context: Imported field-guide summary; primary citation incomplete.

Limitations: No validated human dose, cycle, selectivity or safety framework. Primary study identifier not supplied in the guide entry.

Route: Not documented

  • Peptide Protocol Field Guide · version 7
Open this exact record in the library →Suggest a correction
CONTINUE THE RESEARCH

Follow the pathway.

These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.

Browse this pathway in the library →

Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.